拓新药业 (301089.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−498.8x

Market Cap

CNY 2.93B

MomentumView details →

1D Return

−4.38%

YTD Return

−18.43%

RSI (14)

42.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−498.8x

Market Cap

CNY 2.93B

RSI (14)

42.4

MomentumView details →

1D Return

−4.38%

YTD Return

−18.43%

ProfitabilityView details →

Gross Margin

24.77%

Net Margin

−20.49%

EBITDA Margin

−1.49%

ROE (TTM)

−5.19%

ROA (TTM)

−4.64%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

−8.90%

EPS YoY

—

FCF YoY

+28.86%

Revenue CAGR 3Y

−21.59%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.11x

Quick Ratio

2.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

373.85M

Net Income (TTM)

−76.61M

Op. CF (TTM)

414131.45

Latest newsMore news →

Tuoxin Pharmaceutical's wholly-owned subsidiary Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. held a groundbreaking ceremony for its Active Pharmaceutical Ingredient and Health Dietary Supplement Bio-Manufacturing Base Construction Project in Inner Mongolia.47d ago

Xinxiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tuoxin Pharmaceutical, reached a partnership with Henan Normal University to jointly develop new nucleoside anti-tumor and antiviral drugs including Akangfuding.49d ago

Similar companies

同大股份300321.SZ 新锦动力300157.SZ 永东股份002753.SZ 必创科技300667.SZ 康芝药业300086.SZ 东晶电子002199.SZ

Latest newsMore news →

Tuoxin Pharmaceutical's wholly-owned subsidiary Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. held a groundbreaking ceremony for its Active Pharmaceutical Ingredient and Health Dietary Supplement Bio-Manufacturing Base Construction Project in Inner Mongolia.47d ago Xinxiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tuoxin Pharmaceutical, reached a partnership with Henan Normal University to jointly develop new nucleoside anti-tumor and antiviral drugs including Akangfuding.49d ago